Keros Therapeutics (KROS) reported a first-quarter loss of $1.21 per share, missing consensus estimates as revenue fell sharply following the reset of its partnership with Takeda.
The results reflect a shift in the company’s expense base and revenue profile, with management highlighting a cash runway now extending into the first half of 2028. The biotechnology firm’s near-term results are expected to remain volatile, driven by the timing of partner-related milestone payments rather than repeatable product sales.
The company’s performance versus analyst expectations is detailed below:
Shares of Keros faced pressure as investors weighed the longer cash runway against the sharp earnings and revenue miss. The stock’s performance underscores the uncertainty inherent in pre-commercial biotechnology companies, where valuations are sensitive to clinical trial progress and the timing of partnership revenue.
The steep 99.8% year-over-year revenue decline to $0.4 million highlights the company’s dependence on non-recurring payments. The prior-year period included significant license revenue from Takeda, which was absent in the first quarter of 2026. Total revenue in 2025 was $244.1 million, driven by a $200 million upfront payment and a $10 million development milestone from the Takeda license for elritercept. The current quarter’s revenue consisted only of transition services.
The restructured Takeda deal, which granted exclusive rights to elritercept outside of greater China, has significantly lowered Keros’ operating expenses. First-quarter research and development costs fell 67% year-over-year to $16.1 million as development responsibilities shifted to Takeda. This leaner cost structure helped preserve the company’s cash position, which stood at $281.5 million at the end of the quarter. Keros also completed a $194.4 million tender offer, buying back 35.9% of its outstanding shares.
With Takeda now responsible for elritercept development, investor focus shifts to Keros’ lead wholly-owned program, rinvatercept. The company plans to begin a Phase II study in Duchenne muscular dystrophy in the third quarter of 2026, with initial data expected in the first half of 2027. This positions Keros in a competitive field alongside established players like Sarepta Therapeutics (SRPT) and PTC Therapeutics (PTCT), making clinical differentiation a key factor for future success.
The extended cash runway gives Keros the financial flexibility to pursue its rinvatercept program without immediate financing pressure. However, the company’s valuation will likely depend on delivering positive clinical data and the eventual cadence of milestone payments from its Takeda and Hansoh partnerships.
This article is for informational purposes only and does not constitute investment advice.
